Recent and Upcoming Milestones
Clinical Trials of Novel Antibiotic Combination Approved by SFDA and Initiated
In November 2008, the Company initiated clinical trials of its novel antibiotic combination formula after the SFDA completed its technical analyses and cleared the product for clinical trials. The novel antibiotic combination is a third generation Cephalosporin antibiotic formulated with a bacterial- enzyme inhibitor for the treatment of infections. The inclusion of a bacterial-enzyme inhibitor gives it the potential to address antibiotic- resistant infections, which are on the rise in China.
AMEX Listing Plans Underway
The Company is confident that it meets AMEX listing requirements pending compliance with minimum bid price rules. During senior management's trip to the U.S., the team will continue to discuss listing preparations with specialists and advisors.
Two-Week U.S. Tour in November 2008 to Present at Conferences and Meet Investors
Ms. Zhilin Li, President and CEO, will visit the U.S. for the first
time with senior management to meet investors and participate in two
investor conferences. The U.S. tour will begin on November 10, 2008 in New
York City, where management will present at Rodman and Renshaw's Annual
Global Investment Conference. Management will visit investors in several
other cities, including Los Angeles and San Francisco. The tour will
conclude on November 21, 2008 in Las Vegas, Nevada, where management will
present at Roth Capital's "China Comes to Vegas" conference. M
|SOURCE China Pharma Holdings, Inc.|
Copyright©2008 PR Newswire.
All rights reserved